Autologous stem cell transplantation (ASCT) followed by allogeneic transplantation with reduced-intensity conditioning.
| Author (Ref) . | Patients . | Age (median) . | Auto- logous SCT . | RIC . | GVHD . | TRM . | CR Rate . | Median Follow- Up . | Survival . |
|---|---|---|---|---|---|---|---|---|---|
| * plus fludarabine in 7 cases | |||||||||
| ** 23 unrelated donors | |||||||||
| Abbreviations: Mel, Melphalan; Flu, fludarabine; TBI, total body irradiation; ATG, antithymocyte globulin; aGVHD, acute graft-versus-host disease; cGVHD chronic graft-versus-host disease; SCT, stem cell transplantation; TRM, transplant-related mortality; CR, complete remission; EFS, event-free survival; OS, overall survival | |||||||||
| Maloney (36) | 54 (48% relapsed or refractory MM) | 29–71 (52) | Mel 200 | low-dose* TBI (2 Gy ) | 38.5% aGVHD ≥ II 46% cGVHD | 100 days 2% 1-yr 15% | 52% | 18 m | 2-yr EFS 55% 2-yr OS 78% |
| Kroger (35) | 47** | 31–64 (52) | Mel 200 | Flu/Mel/ATG | 32% aGVHD ≥ II 32% cGVHD | 100 days 6% | 55% | 15 m | 3-yr EFS 54% 3-yr OS 70% |
| Author (Ref) . | Patients . | Age (median) . | Auto- logous SCT . | RIC . | GVHD . | TRM . | CR Rate . | Median Follow- Up . | Survival . |
|---|---|---|---|---|---|---|---|---|---|
| * plus fludarabine in 7 cases | |||||||||
| ** 23 unrelated donors | |||||||||
| Abbreviations: Mel, Melphalan; Flu, fludarabine; TBI, total body irradiation; ATG, antithymocyte globulin; aGVHD, acute graft-versus-host disease; cGVHD chronic graft-versus-host disease; SCT, stem cell transplantation; TRM, transplant-related mortality; CR, complete remission; EFS, event-free survival; OS, overall survival | |||||||||
| Maloney (36) | 54 (48% relapsed or refractory MM) | 29–71 (52) | Mel 200 | low-dose* TBI (2 Gy ) | 38.5% aGVHD ≥ II 46% cGVHD | 100 days 2% 1-yr 15% | 52% | 18 m | 2-yr EFS 55% 2-yr OS 78% |
| Kroger (35) | 47** | 31–64 (52) | Mel 200 | Flu/Mel/ATG | 32% aGVHD ≥ II 32% cGVHD | 100 days 6% | 55% | 15 m | 3-yr EFS 54% 3-yr OS 70% |